Hiprex versus standard management for preventing urinary tract infections post intravesical botox injection for overactive bladder: A randomised controlled trial

Hiprex versus standard management for preventing urinary tract infections post intravesical botox injection in women with overactive bladder: A randomised controlled trial

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12624000500550

Enrollment

118

Registered

2024-04-23

Start date

2024-05-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Urinary tract infections (UTIs) are the most common postoperative complication following Botox injection in the bladder. The risk of UTI is approximately 24%. This study will see if taking a tablet of hiprex twice a day for six weeks could decrease the risk of urinary tract infection after Botox treatment. Hiprex is a medication that reduces the incidence of urinary tract infections in women with repeated urinary tract infections. We are comparing this to our current practice, where no further preventative medications are given other than the standard antibiotics during the procedure that everyone receives.

Interventions

Methanamine Hippurate (Hiprex) 1g oral tablet twice daily for 6 weeks, in addition to intraoperative antibiotics (1-2g intravenous cefazolin, 500 mg cephalexin oral tablet or another if antibiotic allergies) during Botulinum toxin (Botox) injection for overactive bladder. Hiprex treatment will start the evening of the procedure. We will monitor adherence by counting the left over tablets at the 6-week postoperative visit.

Study design

Allocation

Randomised controlled trial

Primary purpose

Prevention

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

• Women aged 18 and over receiving intravesical Botox treatment • Able to give informed consent for participation in the trial

Exclusion criteria

• Age < 18 years • Known renal tract abnormalities • Bladder pain syndrome as indication for Botox • History of recurrent urinary tract infections prior to Botox treatment

Outcome results